Targeted Treatment of HER2-Positive Breast Tumors – Updates from ESMO 2020 Congress
The recent European Society for Medical Oncology (ESMO) Congress took place virtually. We bring you a brief summary of the presentations related to the treatment of HER2-positive breast tumors.
Dual Anti-HER2 Blockade in Combination with Chemotherapy
Based on the results of the CLEOPATRA clinical trial, the combination therapy of trastuzumab, pertuzumab, and docetaxel is used as a standard 1st line treatment in patients with HER2+ locally advanced or metastatic breast tumor. The single-arm clinical trial PERUSE evaluated the efficacy and safety of the combination of trastuzumab and pertuzumab with a taxane of the treating physician's choice. The final results of this study were presented at the congress. Patients with inoperable HER2+ locally advanced or metastatic disease received dual anti-HER2 therapy with docetaxel (54%), paclitaxel (41%), or nab-paclitaxel (5%) until disease progression or unacceptable toxicity.
PERUSE Study Results
A total of 1,436 patients with a median age of 54 years were treated, with a median follow-up time of 69 months. The observed safety profile and treatment efficacy were consistent with the conclusions of the CLEOPATRA study. The median progression-free survival (PFS) for the entire cohort of patients reached 20.7 months (95% confidence interval [CI] 18.9−23.1), and the median overall survival (OS) was 65.3 months (95% CI 60.9−70.9). The median PFS for the docetaxel-treated subgroup was 19.4 months (95% CI 16.9−22.1), patients treated with paclitaxel achieved a PFS of 23.2 months (95% CI 19.6−22.1), and in the nab-paclitaxel group, it was 19.2 months (95% CI 11.7−37.1).
Grade ≥ 3 adverse events were observed in 61% of patients, most commonly neutropenia or diarrhea. Due to adverse events, it was necessary to discontinue pertuzumab therapy in 10% of patients, trastuzumab in 9%, and chemotherapy in 20% of patients.
From Clinical Trials to Real-World Practice
An observational study conducted in 18 Italian hospitals utilized data from all 347 patients treated with the trastuzumab/pertuzumab/taxane combination since pertuzumab entered the market. The chosen taxane was docetaxel in 60% of cases and paclitaxel in 40%. The achieved objective response rate (ORR) to treatment was 77% with a median PFS of 26.9 months (95% CI 20-33.8). The safety profile was in line with available data.
Conclusion
The final results of the PERUSE study and data from real-world clinical practice support the use of the trastuzumab + pertuzumab + taxane combination in the 1st line treatment of locally advanced or metastatic HER2+ breast cancer. Paclitaxel appears to be a valid alternative to docetaxel treatment.
(este)
Sources:
1. Miles D. W., Ciruelos E. M., Schneeweiss A. et al. Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Ann Oncol 2020; 31 (suppl_4): S348−S395, doi: 10.1016/annonc/annonc268. Available at: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/final-results-from-peruse-a-global-study-of-pertuzumab-p-trastuzumab-h-and-investigator-s-chosen-taxane-as-first-line-therapy-for-her2-positi
2. Garrone O., Giarratano T., Michelotti A. et al. From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial. Ann Oncol 2020; 31 (suppl_4): S348−S395, doi: 10.1016/annonc/annonc268. Available at: https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/from-the-cleopatra-study-to-real-life-final-results-from-the-g.o.n.o.-super-trial
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
